The estimated Net Worth of Claudine Bruck is at least $6 dollars as of 11 October 2021. Claudine Bruck owns over 181 units of Navidea Biopharmaceuticals Inc stock worth over $6 and over the last 7 years he sold NAVB stock worth over $0. In addition, he makes $0 as Independent Director at Navidea Biopharmaceuticals Inc.
Claudine has made over 3 trades of the Navidea Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 181 units of NAVB stock worth $5,006 on 11 October 2021.
The largest trade he's ever made was buying 2,550 units of Navidea Biopharmaceuticals Inc stock on 13 May 2019 worth over $4,845. On average, Claudine trades about 252 units every 63 days since 2018. As of 11 October 2021 he still owns at least 6,067 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Claudine Bruck stock trades at the bottom of the page.
Dr. Claudine Bruck serves as Independent Director of the Company. Dr. Bruck has served as a director of Navidea since March 2018. Dr. Bruck is co-founder and has served as Chief Executive Officer of Prolifagen LLC, a start-up company developing a microRNA-based medicine for tissue regeneration, since June 2016. She is also a course director at University of Pennsylvania’s Institute of Translational Medicine and Applied Technology, and Chief Scientific Officer of SAPVAX LLC for which she is a half-time employee to BioMotiv LLC. Dr. Bruck is a member of the board of directors of Annovis Bio, Inc. (ANVS), a biotechnology company focused on development of medicines for neurodegenerative diseases. Dr. Bruck joined GlaxoSmithKline (“GSK”) in 1985 to build GSK’s HIV vaccine program. In her role in GSK’s vaccine group, Dr. Bruck was instrumental in the development of GSK’s HPV vaccine (Cervarix), and headed their cancer vaccine program from inception to Phase 2 before joining the drug discovery group of GSK. She held several roles in the drug discovery group, from Head of Clinical Immunology (2004-2005), to VP and Head of Biology for the Center of Excellence for External Drug Discovery (2005-2008), to VP and Head of a newly formed ophthalmology R&D group (2008-2015). Dr. Bruck holds a Ph.D. in biochemistry from the University of Brussels.
Claudine Bruck is 65, he's been the Independent Director of Navidea Biopharmaceuticals Inc since 2018. There are 1 older and 6 younger executives at Navidea Biopharmaceuticals Inc. The oldest executive at Navidea Biopharmaceuticals Inc is William J. Regan, 69, who is the Chief Strategy Officer & Chief Compliance Officer.
Claudine's mailing address filed with the SEC is C/O ANNOVIS BIO, INC., 101 LINDENWOOD DR, SUITE 225, MALVERN, PA, 19355.
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen, eLife Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: